Mustafa Guzel

This inventor holds 34 USPTO granted patents and 4 published patent applications, plus 4 CIPO patents and 6 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Vtv Therapeutics LLC, Transtech Pharma, Inc., Novo Nordisk A/s. Active years: 2008-2024.

USPTO Granted Patents = 34 (Patent Applications = 4)

% Patents Active = 85.3

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 5)

Average Co-Inventor Count = 7.4

ph-index = 9

Forward Citations = 524(Granted Patents)

Company Filing History:

Transtech Pharma, Inc.

High Point Pharmaceuticals, LLC

patents

Years Active: 2008-2024

Loading Chart...

Areas of Expertise:

Imidazole Derivatives

Tricyclic Compounds

PDE4 Inhibitors

Diabetes Treatment

Aryl Carbonyl Derivatives

Pharmaceutical Compositions

TNF-alpha Modulators

Oxadiazoanthracene Compounds

Azoanthracene Derivatives

Therapeutic Agents

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12091407 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof (2024-09-17),

2. 11649230 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof (2023-05-16),

3. 11130753 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof (2021-09-28),

4. 10889580 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof (2021-01-12),

5. 10570126 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof (2020-02-25),

6. 10568888 - Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors (2020-02-25),

7. 10391097 - Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors (2019-08-27),

8. 10287284 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof (2019-05-14),

9. 10085990 - Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors (2018-10-02),

10. 10030011 - Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof (2018-07-24),

11. 9833457 - Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors (2017-12-05),

12. 9687489 - Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors (2017-06-27),

13. 9393245 - Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors (2016-07-19),

14. 9175003 - Substituted azoanthracene derivatives and intermediates for preparation thereof (2015-11-03),

15. 9163022 - Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors (2015-10-20),

Title: Innovations in Pharmaceutical Chemistry: The Work of Mustafa Guzel

Introduction: Mustafa Guzel, a notable inventor based in Jamestown, NC, has made significant contributions to the field of pharmaceutical chemistry. With an impressive portfolio of 34 patents, his work primarily focuses on innovative compounds and their applications in treating various diseases.

Latest Patents: Among his latest inventions are advancements in substituted fused imidazole derivatives. These compounds are not only of interest because of their unique chemical structures but also due to their potential therapeutic uses. Specifically, they are designed to control the activity or quantity of heme-oxygenase, an enzyme that plays a critical role in renal disease management. Guzel's contributions also include methods for the preparation of these derivatives and formulations comprising them, aiming to provide effective pharmaceutical compositions for patients.

Career Highlights: Mustafa Guzel has had a distinguished career, working with renowned companies within the pharmaceutical sector. His experience at VTV Therapeutics LLC and Transtech Pharma, Inc. has allowed him to apply his expertise in drug development and innovation, further enhancing his contributions to the field.

Collaborations: Throughout his professional journey, Guzel has collaborated with other skilled professionals, including Dharma Rao Polisetti and Adnan M M Mjalli. These partnerships have facilitated a rich exchange of ideas and have been pivotal in advancing his research and patent applications.

Conclusion: In conclusion, Mustafa Guzel exemplifies the spirit of innovation in the pharmaceutical industry. His groundbreaking work on substituted fused imidazole derivatives stands as a testament to his dedication and expertise. The impact of his inventions promises to advance our understanding and treatment of renal diseases, highlighting the importance of continued investment in research and development.